Mebeweryna w leczeniu zespołu jelita nadwrażliwego – skuteczność i bezpieczeństwo terapii Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 20, 2022
Słowa kluczowe:
mebeweryna, zespół jelita nadwrażliwego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zespół jelita nadwrażliwego jest przewlekłym, często nawracającym i bardzo rozpowszechnionym zaburzeniem interakcji mózg–jelito. W praktyce klinicznej zespół jelita nadwrażliwego charakteryzuje się przewlekłymi bólami brzucha i zaburzeniami rytmu wypróżnień. Mebeweryna jest muskulotropowym środkiem rozkurczowym o bezpośrednim działaniu na mięśnie gładkie przewodu pokarmowego, który łagodzi skurczowe bóle brzucha, nie zaburzając prawidłowej motoryki jelit. W artykule przedstawiono aktualne dane oceniające skuteczność i bezpieczeństwo stosowania mebeweryny w zespole jelita nadwrażliwego na podstawie systematycznego przeglądu literatury opublikowanego w 2022 r.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska, A. (2022). Mebeweryna w leczeniu zespołu jelita nadwrażliwego – skuteczność i bezpieczeństwo terapii . Medycyna Faktów , 15(2(55), 205-208. https://doi.org/10.24292/01.MF.0222.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016; 150: 1262-79.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13(4): 1-30.
3. Lacy BE, Pimentel M, Brenner DM et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021; 116: 17-44.
4. Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214-40.
5. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The efficacy of mebeverine in the treatment of irritable bowel syndrome – a systematic review. J Clin Med. 2022; 11: 1044.
6. Guslandi M. Mebeverine plus saccharomyces boulardii versus mebeverine alone in the treatment of irritable bowel syndrome without constipation: A retrospective analysis. Am J Gastroenterol. 2011; 106: S495.
7. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34: 783-93.
8. Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med. 1972; 2: 34-6.
9. Prout BJ. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner. 1983; 227: 1607-8.
10. Capurso L, Koch M, Tarquini M et al. The irritable bowel syndrome. A cross-over study of octylonium bromide, mebeverine and placebo. Clin Trials J. 1984; 21: 285-91.
11. Chakraborty DS, Hazra A, Sil A et al. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Fam Med Prim Care. 2019; 8: 3173-8.
12. Schaffstein W, Panijel M, Luettecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. Curr Res Clin Exp. 1990; 47: 136-45.
13. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23: 105-13.
14. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharm. 1999; 13: 1419-27.
15. Sahib AS. Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol. 2013; 148: 1008-12.
16. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine. J Neurogastroenterol Motil. 2011; 23: 1098-104.
17. Hatami K, Kazemi-Motlagh AH, Ajdarkosh H et al. Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial. Crescent J Med Biol Sci. 2020; 7: 186-94.
18. Mokhtare M, Asadipanah M, Bahardoust M et al. Efficacy of adding Luvos® Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. Biomed Res. 2018; 5: 2776-83.
19. Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract. 1986; 40: 276-8.
20. Inauen W, Halter F. Clinical Efficacy, Safety and Tolerance of Mebeverine Slow Release (200 mg) vs Mebeverine Tablets in Patients with Irritable Bowel Syndrome. Drug Investig. 1994; 8: 234-40.
21. Van Outryve M, Mayeur S, Meeus MA et al. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm. 1995; 20: 277-82.
22. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54: 461-4.
23. Kruis W, Weinzierl M, Schüssler P et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 1986; 34: 196-201.
24. Chang FY, Lu CL, Luo JC et al. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17: 402-10.
25. Lu C, Chen C, Chang F et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15: 925-30.
26. Everitt HA, Moss-Morris RE, Sibelli A et al. Management of irritable bowel syndrome in primary care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol. 2010; 10: 136.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13(4): 1-30.
3. Lacy BE, Pimentel M, Brenner DM et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021; 116: 17-44.
4. Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214-40.
5. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The efficacy of mebeverine in the treatment of irritable bowel syndrome – a systematic review. J Clin Med. 2022; 11: 1044.
6. Guslandi M. Mebeverine plus saccharomyces boulardii versus mebeverine alone in the treatment of irritable bowel syndrome without constipation: A retrospective analysis. Am J Gastroenterol. 2011; 106: S495.
7. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34: 783-93.
8. Baume P. Mebeverine, an effective agent in the irritable colon syndrome. Aust N Z J Med. 1972; 2: 34-6.
9. Prout BJ. The treatment of irritable bowel syndrome. Two doses of mebeverine compared. Practitioner. 1983; 227: 1607-8.
10. Capurso L, Koch M, Tarquini M et al. The irritable bowel syndrome. A cross-over study of octylonium bromide, mebeverine and placebo. Clin Trials J. 1984; 21: 285-91.
11. Chakraborty DS, Hazra A, Sil A et al. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Fam Med Prim Care. 2019; 8: 3173-8.
12. Schaffstein W, Panijel M, Luettecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study. Curr Res Clin Exp. 1990; 47: 136-45.
13. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23: 105-13.
14. Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharm. 1999; 13: 1419-27.
15. Sahib AS. Treatment of irritable bowel syndrome using a selected herbal combination of Iraqi folk medicines. J Ethnopharmacol. 2013; 148: 1008-12.
16. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine. J Neurogastroenterol Motil. 2011; 23: 1098-104.
17. Hatami K, Kazemi-Motlagh AH, Ajdarkosh H et al. Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial. Crescent J Med Biol Sci. 2020; 7: 186-94.
18. Mokhtare M, Asadipanah M, Bahardoust M et al. Efficacy of adding Luvos® Healing Earth supplementation to mebeverine in improving symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial. Biomed Res. 2018; 5: 2776-83.
19. Tudor GJ. A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. Br J Clin Pract. 1986; 40: 276-8.
20. Inauen W, Halter F. Clinical Efficacy, Safety and Tolerance of Mebeverine Slow Release (200 mg) vs Mebeverine Tablets in Patients with Irritable Bowel Syndrome. Drug Investig. 1994; 8: 234-40.
21. Van Outryve M, Mayeur S, Meeus MA et al. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm. 1995; 20: 277-82.
22. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54: 461-4.
23. Kruis W, Weinzierl M, Schüssler P et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion. 1986; 34: 196-201.
24. Chang FY, Lu CL, Luo JC et al. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17: 402-10.
25. Lu C, Chen C, Chang F et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15: 925-30.
26. Everitt HA, Moss-Morris RE, Sibelli A et al. Management of irritable bowel syndrome in primary care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol. 2010; 10: 136.